[Translation] A randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of MWN105 injection after single and multiple subcutaneous administration in healthy Chinese subjects

主要目的：评估MWN105注射液在中国健康受试者中单、多次给药的安全性、耐受性。次要目的：评估MWN105注射液在中国健康受试者中单、多次给药的药代动力学特征。探索性目的：初步评估MWN105注射液在中国健康受试者中的药效学及免疫原性。

[Translation]

Primary objective: To evaluate the safety and tolerability of MWN105 injection after single and multiple administrations in healthy Chinese subjects. Secondary objective: To evaluate the pharmacokinetic characteristics of MWN105 injection after single and multiple administrations in healthy Chinese subjects. Exploratory objective: To preliminarily evaluate the pharmacodynamics and immunogenicity of MWN105 injection in healthy Chinese subjects.

Start Date16 Dec 2024

Sponsor / Collaborator

Shanghai Minwei Biotechnology Co., Ltd

100 Clinical Results associated with GLP-1R x GIPR x FGF21R

100 Translational Medicine associated with GLP-1R x GIPR x FGF21R

0 Patents (Medical) associated with GLP-1R x GIPR x FGF21R

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Who we are

Solutions
Plan
Contact us

What we do

Drug
Clinical Progress
Patent
Literature
Report
News